Janney Montgomery Scott LLC Increases Position in Alnylam Pharmaceuticals, Inc. $ALNY

Janney Montgomery Scott LLC increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 43.6% in the first quarter, HoldingsChannel.com reports. The firm owned 9,339 shares of the biopharmaceutical company’s stock after buying an additional 2,836 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Alnylam Pharmaceuticals were worth $3,090,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ALNY. MV Capital Management Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $29,000. HM Payson & Co. acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $27,000. Ameriflex Group Inc. purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth $32,000. Finally, Golden State Wealth Management LLC raised its position in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 36 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on ALNY shares. Chardan Capital reaffirmed a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Wells Fargo & Company upped their price target on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research report on Friday, May 1st. Royal Bank Of Canada decreased their price target on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a research note on Friday, May 1st. HC Wainwright lowered their price objective on Alnylam Pharmaceuticals from $510.00 to $470.00 and set a “buy” rating on the stock in a report on Monday, June 29th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $461.39.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director David E. I. Pyott sold 3,830 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director owned 1,582 shares of the company’s stock, valued at $473,302.76. This represents a 70.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $321.59 on Wednesday. The firm has a 50 day simple moving average of $295.81 and a 200-day simple moving average of $326.82. The stock has a market cap of $42.94 billion, a price-to-earnings ratio of 87.87 and a beta of 0.27. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals, Inc. has a 1-year low of $273.11 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The firm had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The firm’s quarterly revenue was up 96.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.44) earnings per share. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.